In the present study, we further demonstrated that treatment with the BsAb PD-1-TREM2 scFv, yielded significant anti-tumor effects compared to those of a single treatment targeting PD-1, which was achieved by reducing the tumor infiltration of MDSCs and TAMs and increasing the production of tumor-infiltrating T cells. The gene discussed is TREM2; the disease is neoplasm.